78
Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC www.drugreimbursement.org

Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Embed Size (px)

Citation preview

Page 1: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Drug Reimbursement and the Bottom Line: Update 2009

Anne Jarrett, MS, RPhATJ Consulting, LLC

www.drugreimbursement.org

Page 2: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Disclaimer

I have no relationships with any commercial interests related to my presentation.

Page 3: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

A Real Fairy Tale

A long, long time ago, no one had to worry about the bottom line. Money was plentiful across the land. Drugs were cheaper. We got paid based on AWP.Everyone lived happily ever after.

Page 4: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Inpatient?

Outpatient?OPD?

M.D. owned?

OPPS?IPPS?

NOC?

SCOD?

Rev Code?

HCPCS II ?

Pass –thru?

SI?

ASP?CDM?

Dialysis?

FI?

CF?ICD-9?

DRG?

APC?

UOM? PAL?

Med A?Med B?

Med C?

Med D?

Add B

Packaged?Self adm?

Medicaid?

MS?

SS? IMS?

UB-92?

CMS-1500?

2nd payer?

Carrier? Outlier?

Page 5: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Objectives

• 2009 IPPS and OPPS

• The bottom line

• Why you should care

• Specific knowledge and use

• Key relationships and data

Page 6: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

True or False?• No drug administered to a Medicare

inpatient is separately reimbursed.

• Medical coders look at the drugs patients receive while in the hospital.

• No MS-DRGs mention drugs.

• There are no HCPCS codes that are useful in quality measurement.

Page 7: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

True or False?

• Day hospital patients are inpatients and covered by Medicare A.

• Physician owned clinics/offices use HCPCS codes and fiscal intermediaries.

• In-house dialysis centers and hospitals share a Medicare number.

Page 8: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Objectives

• 2009 IPPS and OPPS

• The bottom line

• Why you should care

• Specific knowledge and use

• Key relationships and data

Page 9: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

2009 Final RulesInpatientProspective Payment System (IPPS)

Page 10: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

IPPS 2009

• 3.6% in national standardized rates

• High-cost outlier threshold to $20,185

• Final 2 year transition to MS-DRGs

• Will not reimburse hospital to which a pt. has been transferred for tPA if given at transferring hospital

Page 11: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

IPPS 2009 (con.)

• Additional quality measures

• Never events, present on admission(POA), readmission rates

• Will continue to reimburse separately for blood clotting factor products when given for approved indications

Page 12: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Value Based Purchasing

• Align payment with quality of care across settings

• Never events

• Present on admission (POA)

• Readmissions

• Repeat visits

Page 13: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

2009 Final Rules Outpatient Prospective Payment System(OPPS)

Page 14: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

OPPS 2009

• ASP + 4% for separately payable, non-pass-through drugs

• ASP + 6% for pass-through drugs

• Pass-through drug list updated

• ASP + 6% for physician offices

• No more pre-administration fee for IVIG

Page 15: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

OPPS 2009 (con.)• Packaging threshold = $60.00

• Drug administration’s APC structure decreased from 6 to 5 APCs

• CMS decided against separating drugs & biologicals into 2 cost centers (high and low) to reflect overhead costs

Page 16: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

ASP + 2%?• CMS calculated ASP + 2% to be

“actual”cost of drugs & biologicals

• Includes acquisition plus pharmacy overhead costs

• 6% 5% 4%

• Future rate?

Page 17: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Objectives

2009 IPPS and OPPS

• The bottom line

• Why you should care

• Specific knowledge and use

• Key relationships and data

Page 18: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

The Bottom Line Equation

Drug prices & usage

+ = Reimbursement

________________ REVENUE

Page 19: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Novation’s National Economic Impact Survey 2009

• Current and future impacts over next 12 months

• 60% of responding hospitals have already been impacted

• 47% foresee staff cuts

Page 20: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Novation’s National Economic Impact Survey (con.)

• 73% have seen costs due to meeting patient safety standards

• 84% plan to spending with 49% anticipating a 6-10% reduction

• 44% will product utilization

Page 21: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Health Leaders Media Industry Survey 2009

• 70% of hospital CEOs concerned that reimbursement cuts will have a “strongly negative effect”

• # 1 wish? “Find a solution to reimbursement cuts.”

Page 22: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

American Hospital Association Study

• “Report of the Economic Crisis: Initial Impact on Hospitals”

• January 2009

• 736 CEOs responded

Page 23: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

AHA Study Results• 59% of hospitals plan on cutting

administrative costs

• 53% Reducing staff

• 27% Reducing services

• 12% Divesting assets

• 8% Considering merger

• 21% Other

Page 24: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Thomson Reuters Study• “Impact of recession on hospitals”

3/2/09

• Median profit margin of U.S. hospitals has declined to ZERO

• Balance sheets of over 400 hospitals nationwide

• Included all sizes and types of hospitals

Page 25: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Out of money experience

Page 26: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

BAILOUT

Page 27: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Example A- Epo• Audit performed on reimbursement of

erythropoietin (epo) given in the hospital outpatient department over four months.

• Performed by Patient Financial Services, Pharmacy and Compliance

• Successful reimbursement rate for Medicare patients = 30%

• Estimated loss of revenue = $100,000 annualized to $300,000

per year

Page 28: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Why Was Revenue Lost? Audit showed*:

50% charged as NESRD when ESRD

25% lacked a lab report

25% charged with wrong billing units

10% charged with expired HCPCS codes

15% charged under incorrect Medicare provider number

*Some bills had multiple errors

*

Page 29: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Example B-Remicade

Infliximab (Remicade®) 100mg vial

• Usual dose = 100mg

• 1 billing unit = 10mg ($55.85)

• If bill for 1 (vial) $55.85

• If bill for 10 billing units $558.50

• Conversion factor = 10

Page 30: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Example C- Botox

• Patients in non-hospital owned pediatric clinic administered Botox

• Clinic ordered Botox from hospital pharmacy

• Hospital pharmacy charged patients for drug

• Hospital gave away thousands of dollars of free drug

Page 31: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Example D - Blood Factor Products

• Hemophilia patient covered by Medicare suffered a fall at his home

• In ICU in a coma for 3 months

• Administered $1.7 million of Factor VIIa

• Hospital did not realize eligibility of reimbursement for inpatients

Page 32: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

BFPs (con.)

• Filed an adjustment claim with Medicare

• The hospital made a couple of million dollars that would have been written off.

Page 33: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Objectives

• 2009 IPPS and OPPS update

• The bottom line

• Why you should care

• Specific knowledge and use

• Key relationships and data

Page 34: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Would you like fries with that?

Page 35: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Objectives

2009 IPPS and OPPS

• The bottom line

• Why you should care

• Specific knowledge and use

• Key relationships and data

Page 36: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Don’t kid yourself. You’re just a deer in the headlights..

Knowledge

Page 37: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Can you answer these questions?

• Can we?

• Will we?

• How much can we?

• Did we?

…..get reimbursed for drug X?

Page 38: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Pt. Location

Payer DrugHCPCsCode

BillingUnit

ICD-9codes

Rev.Code

StatusInd.

The Decks

Page 39: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Flow Of Drug Through Purchasing, Billing, I.S. To Inventory Valuation

Page 40: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Have to know (Hospital)• Fiscal intermediary/carrier/MAC

• Medicare/Medicare numbers

• Information Services (all applicable computer programs)

• Payer mix

• Contracts

• Key players

Page 41: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Have to Know (Pharmacy)• Budget

• Acquisition costs

• Purchasing /GPO contracts/ Wholesaler substitutions

• Information/billing system/staff

• Responsibility reports

Page 42: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Contracts

• Per diem

• Charges -%

• Carve outs

• Specialty drugs

Page 43: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Have to Know Where to Find

• Drug /administration payment rates

• HCPCs codes

• ICD-9 codes

• MS-DRGs/APCs

• Specific patient information

• Changes

Page 44: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

The Ivana Moore Money Health System

You can’t get reimbursed without it.

GOOD► 1/2010THRU

Trans Desc Ins Ch Bill Bill Rev PriceCode Cov In CD1 CD2 CD

Page 45: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

ChargeMaster

• Who is the master of your chargemaster? Has “make or break” effects on revenue capture- could spell disaster

• Multiple chargemasters?

• Hospital chargemaster

Page 46: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Coverage

• International Classification of Diseases,

ninth edition (ICD-9 diagnosis codes)

• Approved indications for drugs

• Local Coverage Determinations (LCD)

• National Coverage Determinations (NCD)

• Pre-approval

• Medical necessity

Page 47: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Pegfilgrastim- LCD (Palmetto GBA)

• ICD-9 codes that support medical necessity:– 205.00 Acute ALL w/o remission– 205.01 Acute ALL w/ remission– 205.10 Chronic ALL w/o remission– 205.11 Chronic CLL w/ remission– 238.7 Neoplasm of uncertain behavior of other

lymphatic and hematopoietic tissues– 288.0 Agranulocytosis– V42.9 Unspecified organ or tissue replaced by

transplant– V59.8 Donors of specified organs or tissue– V66.2 Convalescence following chemo– V66.5 Convalescence following other treatment

Page 48: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Other Payers & Coverage

Page 49: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Did you know?• Medical coders do not look at drugs

when looking through an inpatient’s chart?

• Day hospital pts are considered to be outpatients?

• In-house dialysis units have a separate Medicare number?

Page 50: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Did you know?

• MS-DRGs mention drugs?

• HCPCS codes for quality measures?

• Different drug reimbursement given in hospital outpatient departments, physician owned clinics & ASCs?

Page 51: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Did you know?

• Medicare will reimburse hospitals separately for blood factor products given to hemophilia patients? (Specific ICD-9 diagnosis codes required)

• Med D has and will continue to affect hospitals?

Page 52: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

MS-DRGs That Mention Drugs• Acute ischemic stroke with use of

thrombolytic agent

• Craniotomy with major device implant or acute complex CNS principal diagnosis with MCC or chemotherapeutic implant (Gliadel® wafers)

Page 53: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

HCPCS Codes for Quality Measurement involving drugs

Does your hospital use them?

Example:

G8006 – Acute myocardial infarction

(AMI) patient received Aspirin at

arrival

Page 54: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Quality Measure HCPCS Codes (con.)

• G8006- AMI pt recd aspirin at arrival

• G8012- Pneum pt recv antibiotic 4h

• G8027- HF pt not elig for Bblocker

• G8214- Clini not doc order VTE

Page 55: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Hospital Outpatient Departmentsversus Physician Owned Clinics

• Claim forms

• Addendum B

• Part B Average Sales Price

• HCPCS codes

• Fiscal intermediary

• Carrier

Page 56: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Ambulatory Surgical Centers

• In 2008, CMS started OPPS-like payment

• 65% of OPPS reimbursement rate

• Added 790 ASC procedures

• In 2009, CMS added 30 surgical procedures payable in ASC settings

Page 57: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

How Has MED D Affected Hospitals?

• Manufacturers’ Medication Assistance Programs

• Former program patients can’t afford their co-pays, don’t take meds (e.g transplant meds after 3 years)

• Re-admissions and E.D. visits • Donut hole by July

Page 58: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Resources?

• Fiscal intermediary, carrier, MAC

• Medicare website

http://www.cms.hhs.gov

Page 59: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Finding the needle is easy. Finding the right haystack? Impossible!

FUTILITY

Page 60: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Have to Think About• Appropriate use

• Collaborative guidelines

• Replacement programs

• Charge for wastage?

• Patient Assistance Program

• LOS and outpatient drug affordability

Page 61: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Pharmaceutical Reimbursement Specialist

• Do you have a pharmaceutical reimbursement specialist?

• If you have a business person on staff, does he or she “speak” pharmacy ?

Page 62: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Watch For

• Drug reps distributing information to M.D.s about off-label/ new drug use

• GPO contracts

• Wholesaler substitution

• “Gray market”use

• New drugs without a HCPCS code

Page 63: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Readmissions and E.D.Visits

• Annals of Internal Medicine, 2/3/2009:

“Pharmacists follow up helps cut hospital readmissions and E.R. use by 30% at a Boston hospital”

• Patient Assistance Programs

• Replacement programs

• Cost of drug vs. cost of admission

Page 64: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Rounding Doses

• “Minor decrease in calculated doses result in substantial cost savings without more risk to patients” Oxaliplatin (Eloxatin)

• $17,905/year stage III advanced colorectal CA

• $25,876 for stage IV

• Wastage avoided

(Presented @ GI Cancer Symposium (ASCO), January 19, 2009)

Page 65: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Specialty Pharmacies & Exclusivity

• Some payers restrict certain high cost drugs to specialty pharmacies

• In contract—get involved!

• Some manufacturers grant exclusivity of purchasing to certain entities

Page 66: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Objectives

• 2009 IPPS and OPPS update

• The bottom line

• Why you should care

• Specific knowledge and use

• Key relationships and data

Page 67: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

PUT THE PUZZLE TOGETHER

PHARMACY

MEDICALCODINGBILLING

INFORMATIONSERVICES

PHYSICIANS

REIMBURSEMENTACCOUNTING

Page 68: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

PERSISTANCE

Go ahead. Give yourself permission to be irritating.

Page 69: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

In the Know

– Finance department– Reimbursement accounting– Billing and Collections– Social work– Medicare/Medicaid– Contracting– CFO– Compliance

Page 70: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Challenges CFOs Face• MS-DRGs

• Charge to cost based

• Medicare Recovery Audit Contractor RACs Audits

• ICD-10-CM

• Pay for performance

• Consumer directed health care

Page 71: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Data• Information systems

• Payer mix

• Co-pay collection rate

• Contracts

• Reimbursement rate

• Indigent and charity care

Page 72: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Need to Know• Negotiated carve-outs

• Top MS-DRGs/APCs by dollar

• Outlier payments

• Benchmarks

• Cost to charge ratio

• Base payment

Page 73: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Stay ahead of the train

Finally you see the light at the end of the tunnel. It’s a train coming down the tracks.

Page 74: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Keep Up

• Make yourself aware of all the numerous changes in a timely manner

The only thing that stays constant is change.

Page 75: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

The Future?

Page 76: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Healthcare Reform

This is your government

This is your Government on drugs

Page 77: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

Government Efficiency

Page 78: Drug Reimbursement and the Bottom Line: Update 2009 Anne Jarrett, MS, RPh ATJ Consulting, LLC

You can’t afford not to buy it !

Reimbursitol®

NEW!